115 related articles for article (PubMed ID: 6480460)
1. A phase I clinical study of Nimorazole as a hypoxic radiosensitizer.
Timothy AR; Overgaard J; Overgaard M
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1765-8. PubMed ID: 6480460
[TBL] [Abstract][Full Text] [Related]
2. Studies of the pharmacokinetic properties of nimorazole.
Overgaard J; Overgaard M; Timothy AR
Br J Cancer; 1983 Jul; 48(1):27-34. PubMed ID: 6871077
[TBL] [Abstract][Full Text] [Related]
3. A comparative investigation of nimorazole and misonidazole as hypoxic radiosensitizers in a C3H mammary carcinoma in vivo.
Overgaard J; Overgaard M; Nielsen OS; Pedersen AK; Timothy AR
Br J Cancer; 1982 Dec; 46(6):904-11. PubMed ID: 7150484
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of the hypoxic cell radiosensitizer Ro-03-8799.
Roberts JT; Bleehen NM; Workman P; Walton MI
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1755-8. PubMed ID: 6480458
[TBL] [Abstract][Full Text] [Related]
5. The clinical testing of Ro 03-8799--pharmacokinetics, toxicology, tissue and tumor concentrations.
Saunders MI; Anderson PJ; Bennett MH; Dische S; Minchinton A; Stratford MR; Tothill M
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1759-63. PubMed ID: 6480459
[TBL] [Abstract][Full Text] [Related]
6. The radiosensitizer Ro 03-8799 and the concentrations which may be achieved in human tumours: a preliminary study.
Saunders MI; Dische S; Fermont D; Bishop A; Lenox-Smith I; Allen JG; Malcolm SL
Br J Cancer; 1982 Nov; 46(5):706-10. PubMed ID: 7171452
[TBL] [Abstract][Full Text] [Related]
7. Pilot study of nimorazole as a hypoxic-cell sensitizer with the "chart" regimen in head and neck cancer.
Cottrill CP; Bishop K; Walton MI; Henk JM
Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):807-10. PubMed ID: 9845101
[TBL] [Abstract][Full Text] [Related]
8. Reevaluation of the radiosensitizing effects of sanazole and nimorazole in vitro and in vivo.
Sugie C; Shibamoto Y; Ito M; Ogino H; Suzuki H; Uto Y; Nagasawa H; Hori H
J Radiat Res; 2005 Dec; 46(4):453-9. PubMed ID: 16394636
[TBL] [Abstract][Full Text] [Related]
9. Initial report of the phase I trial of the hypoxic cell radiosensitizer SR-2508.
Coleman CN; Urtasun RC; Wasserman TH; Hancock S; Harris JW; Halsey J; Hirst VK
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1749-53. PubMed ID: 6237086
[TBL] [Abstract][Full Text] [Related]
10. Compliance and toxicity of the hypoxic radiosensitizer nimorazole in the treatment of patients with head and neck squamous cell carcinoma (HNSCC).
Metwally MA; Frederiksen KD; Overgaard J
Acta Oncol; 2014 May; 53(5):654-61. PubMed ID: 24328536
[TBL] [Abstract][Full Text] [Related]
11. Study of the population pharmacokinetic characteristics of nimorazole in head and neck cancer patients treated in the DAHANCA-5 trial.
Hassan Metwally MA; Jansen JA; Overgaard J
Clin Oncol (R Coll Radiol); 2015 Mar; 27(3):168-75. PubMed ID: 25530485
[TBL] [Abstract][Full Text] [Related]
12. Desmethylmisonidazole (Ro 05-9963): clinical pharmacokinetics after multiple oral administration.
Stratford MR; Minchinton AI; Dische S; Saunders MI; Anderson P
Int J Radiat Oncol Biol Phys; 1982; 8(3-4):377-9. PubMed ID: 7107355
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of the combination of two hypoxic cell radiosensitizers, Ro 03-8799 and SR-2508: toxicity and pharmacokinetics.
Newman HF; Bleehen NM; Workman P
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1113-6. PubMed ID: 2943709
[TBL] [Abstract][Full Text] [Related]
14. Interactions of radiation, cyclophosphamide and nimorazole in a C3H mammary carcinoma in vivo.
Zachariae C; Overgaard J
Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1445-8. PubMed ID: 3759571
[TBL] [Abstract][Full Text] [Related]
15. Clinical trials of radiosensitizers: what should we expect?
Brown JM
Int J Radiat Oncol Biol Phys; 1984 Mar; 10(3):425-9. PubMed ID: 6231272
[TBL] [Abstract][Full Text] [Related]
16. Chemical sensitizers for hypoxic cells: a decade of experience in clinical radiotherapy.
Dische S
Radiother Oncol; 1985 Feb; 3(2):97-115. PubMed ID: 3157206
[TBL] [Abstract][Full Text] [Related]
17. Relationship between the neurotoxicity of the hypoxic cell radiosensitizer SR 2508 and the pharmacokinetic profile.
Coleman CN; Halsey J; Cox RS; Hirst VK; Blaschke T; Howes AE; Wasserman TH; Urtasun RC; Pajak T; Hancock S
Cancer Res; 1987 Jan; 47(1):319-22. PubMed ID: 3024818
[TBL] [Abstract][Full Text] [Related]
18. A drug for improved radiosensitization in radiotherapy.
Dische S; Fowler JF; Saunders MI; Stratford MR; Anderson P; Minchinton AI; Lee ME
Br J Cancer; 1980 Jul; 42(1):153-5. PubMed ID: 7426325
[No Abstract] [Full Text] [Related]
19. Pharmacokinetic and metabolic studies of the hypoxic cell radiosensitizer misonidazole.
Flockhart IR; Large P; Troup D; Malcolm SL; Marten TR
Xenobiotica; 1978 Feb; 8(2):97-105. PubMed ID: 415443
[TBL] [Abstract][Full Text] [Related]
20. Concentrations achieved in human tumors after administration of misonidazole, SR-2508 and Ro 03-8799.
Dische S; Saunders MI; Dunphy EP; Bennett MH; Des Rochers C; Stratford MR; Minchinton AI; Orchard RA
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1109-11. PubMed ID: 2943708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
